Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global metabolic disorder therapeutics market size was exhibited at USD 66.19 billion in 2022 and is projected to hit around USD 133.9 billion by 2032, growing at a CAGR of 7.3% during the forecast period 2023 to 2032.

Key Pointers:

• North America was the largest regional market in 2022 and will maintain the trend in future due to the presence of key companies and rising cases of diabetes and obesity
• Diabetes segment led the metabolic disorder therapeutics market in 2022, in terms of revenue generation,owing to higher prevalence and drug usage
• Obesity segment is expected to register a CAGR of 9.28% over the forecast period owing to increasing prevalence as a result of sedentary lifestyle changes
• Drug therapy was the most-preferred therapy due to its high reliability proven success and availability of various types of drugs to treat metabolic diseases
• The segment is expected to maintain its dominance even during the forecast years due to the introduction of smart technology to deliver antidiabetic drug on a regulated basis
• Most of these companies are focusing on strategies, such as collaborations, expansion of product portfolios, and M&A to maintain their industry position
• Oral route of administration was the key revenue-generating segment in 2022 owing to its benefits, such as high reliability and ease of administration

Metabolic Disorder Therapeutics Market Report Scope

Metabolism is the process through which the body generates energy from food. Food comprises biomolecules, including carbohydrates, proteins, and fats. Chemicals in the digestive system are used to break the food into sugars and acids. Metabolic disorders disrupt the normal function of metabolic processes and lead to excess or lack of essential components that are needed to stay healthy. These disorders are either inherited or acquired during the lifetime of an individual.

Factors such as increase in the cases of metabolic disorders, rise in awareness about the availability of therapeutics for metabolic disorders, increase in demand for one-time therapies for metabolic disorders, commencement of patient assistance programs for providing treatment for a range of metabolic disorders, rapid advancements in technology, rise in the prevalence of diabetes and obesity, and initiatives were undertaken by the government are expected to drive the metabolic disorder therapeutics market in the coming years. However, low compliance and adherence rates for metabolic disorder therapies and the availability of alternative options for treatment are expected to hinder the metabolic disorder therapeutics market during the forecast period.

According to the Centers for Disease Control and Prevention (CDC), having increased blood cholesterol puts people at risk of heart disease, and it is considered to be the leading cause of death in the U.S. The risk of heart disease for people with high cholesterol is about twice as high compared to that for people with low cholesterol. Approximately 71 million adults in the U.S. are estimated to have high low-density lipoproteins (LDL) or bad cholesterol. About 7% of children and adolescents between the ages of 6 and 19 have high total cholesterol. High cholesterol has no symptoms. Therefore, many people do not know about their high cholesterol level. A simple blood test can be used to check the cholesterol level of a person.

The metabolic disorder therapeutics market can be segmented based on disease, product, and region. In terms of disease, the metabolic disorder therapeutics market can be divided into lysosomal storage disease, diabetes, obesity, and hypercholesterolemia. The diabetes segment is anticipated to dominate the market because of the extensive use of metabolic disease therapies in anti-diabetic injections and drugs and injections for controlling the blood sugar levels. Based on product, the metabolic disorder therapeutics market can be classified into metachromatic leukodystrophy, hepatic encephalopathy, globoid leukodystrophy, and others.

In terms of region, the metabolic disorder therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the metabolic disorder therapeutics market, due to the presence of key players, rise in prevalence of diabetes and obesity, well-developed health care infrastructure, and increase in health care expenditure. The metabolic disorder therapeutics market in the Asia Pacific is expected to expand at a rapid pace. Increase in patient population, rise in economic development, increase in government initiatives, and rise in awareness are factors propelling the metabolic disorder therapeutics market in the Asia Pacific.

Some of the prominent players in the Metabolic Disorder Therapeutics Market include:

• Novo Nordisk A/S
• Sanofi S.A.
• Boehringer Ingelheim GmbH
• Eli Lilly and Company
• Merck KgaAAmgen, Inc.
• AstraZeneca PLC
• Actelion Pharmaceuticals Ltd.
• Shire PLCAbbVie, Inc.
• Biocon Ltd.
• BioMarin Pharmaceutical, Inc.
• Bristol-Myers Squibb Company
• Cipla, Inc.
• CymaBay Therapeutics, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Metabolic Disorder Therapeutics market.

By Disease 

• Lysosomal Storage Diseases
  • Gaucher’s Disease
  • Metachromatic Leukodystrophy
  • Hurler - Scheie
  • Sanfilipo A
  • Others
• Diabetes
• Obesity
• Inherited Metabolic Disorders
• Hypercholesterolemia

By Therapy Type 

• Enzyme Replacement Therapy
• Cellular Transplantation
• Small Molecule Based Therapy
• Substrate Reduction Therapy
• Gene Therapy
• Drug Therapy

By Route of Administration 

• Oral
• Parenteral
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)